No Data
HK Stock MarketDetailed Quotes
08622 HUAKANG BIOMED
Watchlist
0.114
0.0000.00%
Not Open 11/28 16:08 CST
0.000High0.000Low0Volume
0.114Open0.114Pre Close0.00Turnover0.00%Turnover RatioLossP/E (TTM)47.71MMarket Cap0.24552wk HighLossP/E (Static)418.47MShares0.10852wk Low0.80P/B47.71MFloat Cap0.540Historical High--Dividend TTM418.47MShs Float0.091Historical Low--Dividend LFY0.00%Amplitude--Div YieldTTM--Avg Price8000Lot Size--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About HUAKANG BIOMED Company
Huakang Biomedical Holdings Co., Ltd. is a medical device group focusing on the development, production and sale of various in vitro diagnostic reagents in China. With our knowledge and experience, the Group focuses on the market of male infertility in vitro diagnostic reagents in China. According to the Insight Consulting Report, in terms of procurement value of medical institutions, we ranked third among manufacturers of in-vitro diagnostic reagents for male infertility in China in 2017, accounting for 14.3% of the market share. We have developed a diverse product portfolio of in vitro diagnostic reagents for male infertility. In 2017, it was the largest number of products registered by the China Food and Drug Administration and the Provincial Food and Drug Administration among all manufacturers. One of our parasite series detection reagents is one of only two in vitro diagnostic reagents for hepatosomiasis produced and sold in China approved by the China Food and Drug Administration. Shenzhen Huakang Biomedical Engineering Co., Ltd. (previously known as Shenzhen Moon Bay Biotechnology Co., Ltd. and Shenzhen Nan Fung Biotechnology Co., Ltd.), a limited company established under Chinese law on June 26, 1992, is a wholly-owned subsidiary of the Company. Our portfolio of in vitro diagnostic reagents includes: (i) Male infertility in vitro diagnostic reagents (ii) A series of parasite detection reagents and (iii) Combinations of in vitro diagnostic reagents including EBV detection reagents. R&D capability is one of our main competitive advantages. In 2011, for the first time, we were recognized as a “National High-tech Enterprise” by relevant Chinese government agencies. We sell our products to hospitals and medical institutions in China through direct sales and our distributors. These hospitals and medical institutions use our products for clinical diagnostic tests.
Revenue Breakdown
Business
Unit:CNY
Stock NameRevenueRatio
生物制剂及辅助生育用品和设备11.4M99.45%
健康产品及保健品63K0.55%
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--